Lacipil (Lacidipine)

Lacidipine blocks L‑type calcium channels on vascular smooth‑muscle cells, preventing calcium entry that triggers contraction. The resulting smooth‑muscle relaxation dilates arteries, decreases peripheral resistance, and lowers arterial pressure, providing a sustained antihypertensive effect.

The dosage of Lacipil is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant therapies. The prescriber determines the appropriate strength and titration schedule.

Safety data for lacidipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and alternative therapies are preferred when possible.

To request Lacipil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lacipil belongs to the calcium‑channel‑blocker class, offering potent vasodilation with a long‑acting profile. Compared with beta‑blockers or ACE inhibitors, it may be preferred in patients with asthma or certain metabolic conditions, but drug choice depends on individual comorbidities, tolerability, and physician judgment.

Lacipil tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid exposure to extreme temperatures or humidity.

Lacipil is taken orally, usually once daily with or without food, as directed by the prescribing healthcare professional. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, angioedema, hepatic dysfunction, and myocardial infarction. Patients should be educated to seek immediate medical attention if they experience sudden swelling of the face or throat, marked dizziness, chest pain, or signs of liver injury.

Lacipil is contraindicated in individuals with known hypersensitivity to lacidipine or any component of the formulation. It should also be avoided in patients with severe hepatic impairment, unstable angina, or those taking drugs that strongly inhibit CYP3A4 without appropriate monitoring.